These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 28493496

  • 1. A New Potent Inhibitor of Glycogen Phosphorylase Reveals the Basicity of the Catalytic Site.
    Mamais M, Degli Esposti A, Kouloumoundra V, Gustavsson T, Monti F, Venturini A, Chrysina ED, Markovitsi D, Gimisis T.
    Chemistry; 2017 Jul 03; 23(37):8800-8805. PubMed ID: 28493496
    [Abstract] [Full Text] [Related]

  • 2. Multiscale time-resolved fluorescence study of a glycogen phosphorylase inhibitor combined with quantum chemistry calculations.
    Maffeis V, Mavreas K, Monti F, Mamais M, Gustavsson T, Chrysina ED, Markovitsi D, Gimisis T, Venturini A.
    Phys Chem Chem Phys; 2019 Apr 03; 21(14):7685-7696. PubMed ID: 30912774
    [Abstract] [Full Text] [Related]

  • 3. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
    Alexacou KM, Hayes JM, Tiraidis C, Zographos SE, Leonidas DD, Chrysina ED, Archontis G, Oikonomakos NG, Paul JV, Varghese B, Loganathan D.
    Proteins; 2008 May 15; 71(3):1307-23. PubMed ID: 18041758
    [Abstract] [Full Text] [Related]

  • 4. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.
    Tsitsanou KE, Hayes JM, Keramioti M, Mamais M, Oikonomakos NG, Kato A, Leonidas DD, Zographos SE.
    Food Chem Toxicol; 2013 Nov 15; 61():14-27. PubMed ID: 23279842
    [Abstract] [Full Text] [Related]

  • 5. A multidisciplinary study of 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors.
    Kun S, Begum J, Kyriakis E, Stamati ECV, Barkas TA, Szennyes E, Bokor É, Szabó KE, Stravodimos GA, Sipos Á, Docsa T, Gergely P, Moffatt C, Patraskaki MS, Kokolaki MC, Gkerdi A, Skamnaki VT, Leonidas DD, Somsák L, Hayes JM.
    Eur J Med Chem; 2018 Mar 10; 147():266-278. PubMed ID: 29453094
    [Abstract] [Full Text] [Related]

  • 6. High Consistency of Structure-Based Design and X-Ray Crystallography: Design, Synthesis, Kinetic Evaluation and Crystallographic Binding Mode Determination of Biphenyl-N-acyl-β-d-Glucopyranosylamines as Glycogen Phosphorylase Inhibitors.
    Fischer T, Koulas SM, Tsagkarakou AS, Kyriakis E, Stravodimos GA, Skamnaki VT, Liggri PGV, Zographos SE, Riedl R, Leonidas DD.
    Molecules; 2019 Apr 03; 24(7):. PubMed ID: 30987252
    [Abstract] [Full Text] [Related]

  • 7. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG, Somsák L.
    Curr Opin Investig Drugs; 2008 Apr 03; 9(4):379-95. PubMed ID: 18393105
    [Abstract] [Full Text] [Related]

  • 8. Kinetic and crystallographic studies of glucopyranose spirohydantoin and glucopyranosylamine analogs inhibitors of glycogen phosphorylase.
    Watson KA, Chrysina ED, Tsitsanou KE, Zographos SE, Archontis G, Fleet GW, Oikonomakos NG.
    Proteins; 2005 Dec 01; 61(4):966-83. PubMed ID: 16222658
    [Abstract] [Full Text] [Related]

  • 9. Computation as a tool for glycogen phosphorylase inhibitor design.
    Hayes JM, Leonidas DD.
    Mini Rev Med Chem; 2010 Oct 01; 10(12):1156-74. PubMed ID: 20716053
    [Abstract] [Full Text] [Related]

  • 10. Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.
    Benltifa M, Hayes JM, Vidal S, Gueyrard D, Goekjian PG, Praly JP, Kizilis G, Tiraidis C, Alexacou KM, Chrysina ED, Zographos SE, Leonidas DD, Archontis G, Oikonomakos NG.
    Bioorg Med Chem; 2009 Oct 15; 17(20):7368-80. PubMed ID: 19781947
    [Abstract] [Full Text] [Related]

  • 11. Halogen-substituted (C-β-D-glucopyranosyl)-hydroquinone regioisomers: synthesis, enzymatic evaluation and their binding to glycogen phosphorylase.
    Alexacou KM, Zhang YZ, Praly JP, Zographos SE, Chrysina ED, Oikonomakos NG, Leonidas DD.
    Bioorg Med Chem; 2011 Sep 01; 19(17):5125-36. PubMed ID: 21821421
    [Abstract] [Full Text] [Related]

  • 12. The glycogen phosphorylase inhibitor 2-(3-benzylamino-2-oxo-1,2-dihydropyridin-1-yl)-N-(3,4-dichlorobenzyl)acetamide.
    Popova I, Healy PC, Loughlin WA, Karis ND, Jenkins ID.
    Acta Crystallogr C; 2013 Nov 01; 69(Pt 11):1408-10. PubMed ID: 24192198
    [Abstract] [Full Text] [Related]

  • 13. Glycogen phosphorylase inhibitors: a free energy perturbation analysis of glucopyranose spirohydantoin analogues.
    Archontis G, Watson KA, Xie Q, Andreou G, Chrysina ED, Zographos SE, Oikonomakos NG, Karplus M.
    Proteins; 2005 Dec 01; 61(4):984-98. PubMed ID: 16245298
    [Abstract] [Full Text] [Related]

  • 14. Probing the β-pocket of the active site of human liver glycogen phosphorylase with 3-(C-β-d-glucopyranosyl)-5-(4-substituted-phenyl)-1, 2, 4-triazole inhibitors.
    Kyriakis E, Solovou TGA, Kun S, Czifrák K, Szőcs B, Juhász L, Bokor É, Stravodimos GA, Kantsadi AL, Chatzileontiadou DSM, Skamnaki VT, Somsák L, Leonidas DD.
    Bioorg Chem; 2018 Apr 01; 77():485-493. PubMed ID: 29454281
    [Abstract] [Full Text] [Related]

  • 15. Recent advances in the allosteric inhibition of glycogen phosphorylase.
    Loughlin WA.
    Mini Rev Med Chem; 2010 Oct 01; 10(12):1139-55. PubMed ID: 20716052
    [Abstract] [Full Text] [Related]

  • 16. The σ-hole phenomenon of halogen atoms forms the structural basis of the strong inhibitory potency of C5 halogen substituted glucopyranosyl nucleosides towards glycogen phosphorylase b.
    Kantsadi AL, Hayes JM, Manta S, Skamnaki VT, Kiritsis C, Psarra AM, Koutsogiannis Z, Dimopoulou A, Theofanous S, Nikoleousakos N, Zoumpoulakis P, Kontou M, Papadopoulos G, Zographos SE, Komiotis D, Leonidas DD.
    ChemMedChem; 2012 Apr 01; 7(4):722-32. PubMed ID: 22267166
    [Abstract] [Full Text] [Related]

  • 17. 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies.
    Tsirkone VG, Tsoukala E, Lamprakis C, Manta S, Hayes JM, Skamnaki VT, Drakou C, Zographos SE, Komiotis D, Leonidas DD.
    Bioorg Med Chem; 2010 May 15; 18(10):3413-25. PubMed ID: 20430629
    [Abstract] [Full Text] [Related]

  • 18. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 19. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy.
    Oikonomakos NG.
    Curr Protein Pept Sci; 2002 Dec 01; 3(6):561-86. PubMed ID: 12470212
    [Abstract] [Full Text] [Related]

  • 20. Glucopyranosylidene-spiro-imidazolinones, a New Ring System: Synthesis and Evaluation as Glycogen Phosphorylase Inhibitors by Enzyme Kinetics and X-ray Crystallography.
    Szabó KE, Kyriakis E, Psarra AG, Karra AG, Sipos Á, Docsa T, Stravodimos GA, Katsidou E, Skamnaki VT, Liggri PGV, Zographos SE, Mándi A, Király SB, Kurtán T, Leonidas DD, Somsák L.
    J Med Chem; 2019 Jul 11; 62(13):6116-6136. PubMed ID: 31251604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.